2010
DOI: 10.1016/j.cell.2010.02.039
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and oc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

15
256
0
3

Year Published

2011
2011
2023
2023

Publication Types

Select...
7

Relationship

4
3

Authors

Journals

citations
Cited by 238 publications
(274 citation statements)
references
References 68 publications
15
256
0
3
Order By: Relevance
“…A possible implication of these findings is that PlGF blockade might inhibit disease processes more selectively than physiological homeostasis and thus evoke fewer side effects. We summarize below the findings on PlGF's (Foidart et al 2009;Furuya et al 2011) Heart PlGF-induced revascularization of ischemic myocardium and vessel enlargement in remote myocardium preserve cardiac performance following infarction (Luttun et al 2002;Kolakowski et al 2006;Roncal et al 2008) Knockout: impaired angiogenesis and inflammation in infarct border (Carmeliet et al 2001) Knockout: Normal exercise induces angiogenesis (Gigante et al 2004) Skeletal muscle PlGF protein or gene delivery: enhances angiogenesis, collateral growth, and blood flow in ischemic limb (Luttun et al 2002;Pipp et al 2003;Babiak et al 2004); restores microcirculation in aged dystrophic muscle (Gargioli et al 2008) Knockout: impaired collateral growth in ischemic limb (Carmeliet et al 2001;Scholz et al 2003;Gigante et al 2006) Knockout: normal exercise-induced angiogenesis (Gigante et al 2004) Eye PlGF prevents vessel obliteration in hyperoxia without including neovascularization (Shih et al 2003) Local ocular PlGF protein or gene transfer causes hematoretinal barrier breakdown and edema (Miyamoto et al 2007;Kowalczuk et al 2011) Knockout or aPlGF: impaired choroidal neovascularization (Carmeliet et al 2001;Rakic et al 2003;Van de Veire et al 2010) Knockout or aPlGF does not impair retinal vascularization during development (Carmeliet et al 2001;Feeney et al 2003 (Carmeliet et al 2001;Scholz et al 2003;Gigante et al 2006) (Eriksson et al 2002;Xu et al 2006;Schomber et al 2007;Tarallo et al 2010) PlGF educates CD34 þ progenitors to proangiogenic CD11b þ myelomonocytes in breast cancer (Laurent et al 2011...…”
Section: Plgf a Disease-modifying Candidatementioning
confidence: 99%
See 3 more Smart Citations
“…A possible implication of these findings is that PlGF blockade might inhibit disease processes more selectively than physiological homeostasis and thus evoke fewer side effects. We summarize below the findings on PlGF's (Foidart et al 2009;Furuya et al 2011) Heart PlGF-induced revascularization of ischemic myocardium and vessel enlargement in remote myocardium preserve cardiac performance following infarction (Luttun et al 2002;Kolakowski et al 2006;Roncal et al 2008) Knockout: impaired angiogenesis and inflammation in infarct border (Carmeliet et al 2001) Knockout: Normal exercise induces angiogenesis (Gigante et al 2004) Skeletal muscle PlGF protein or gene delivery: enhances angiogenesis, collateral growth, and blood flow in ischemic limb (Luttun et al 2002;Pipp et al 2003;Babiak et al 2004); restores microcirculation in aged dystrophic muscle (Gargioli et al 2008) Knockout: impaired collateral growth in ischemic limb (Carmeliet et al 2001;Scholz et al 2003;Gigante et al 2006) Knockout: normal exercise-induced angiogenesis (Gigante et al 2004) Eye PlGF prevents vessel obliteration in hyperoxia without including neovascularization (Shih et al 2003) Local ocular PlGF protein or gene transfer causes hematoretinal barrier breakdown and edema (Miyamoto et al 2007;Kowalczuk et al 2011) Knockout or aPlGF: impaired choroidal neovascularization (Carmeliet et al 2001;Rakic et al 2003;Van de Veire et al 2010) Knockout or aPlGF does not impair retinal vascularization during development (Carmeliet et al 2001;Feeney et al 2003 (Carmeliet et al 2001;Scholz et al 2003;Gigante et al 2006) (Eriksson et al 2002;Xu et al 2006;Schomber et al 2007;Tarallo et al 2010) PlGF educates CD34 þ progenitors to proangiogenic CD11b þ myelomonocytes in breast cancer (Laurent et al 2011...…”
Section: Plgf a Disease-modifying Candidatementioning
confidence: 99%
“…Current treatment of CNV in human AMD by VEGF blockade offers visual improvement but requires intravitreal injection and can increase the risk of stroke, ischemic heart disease, and adverse ocular events (Mitchell et al 2010). Genetic blockage of PlGF or pharmacological inhibition of PlGF by systemic administration of an anti-PlGF mAb inhibits laser-induced CNV in mice ( Van de Veire et al 2010). Combination therapy with an anti-PlGF and anti-VEGFR2 mAb is also more effective than monotherapy with anti-PlGF mAb alone.…”
Section: Diseases With Improved Outcome Following Plgf Blockade Oculamentioning
confidence: 99%
See 2 more Smart Citations
“…Hence, neutralizing PlGF in addition to VEGF at the onset may be more effective than a single target approach. However, this strategy is not without controversy, as conflicting reports exist on the basis of results generated in preclinical studies (35,36). The value of a combinatorial approach against VEGF and PlGF will ultimately need to be determined in a clinical setting in a heterogeneous patient population that receives not only antiangiogenic therapy but also other modalities of treatment such as radiation and chemotherapy.…”
Section: Discussionmentioning
confidence: 99%